EUCTR2006-003709-15-HU进行中（未招募）不适用
A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin (Pre- and Post Chemotherapy and Pre-Chemotherapy only) for Reduction in Severity of Oral Mucositis in Subjects with Multiple Myeloma (MM) Receiving High Dose Melphalan followed by Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)
Biovitrum AB (publ)0 个研究点开始时间: 2006年10月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
招募中
2 期
To study the effect of Turmeric-Boswellia combination in females with menstrual pain.CTRI/2024/07/070121Arjuna Natural Private Limited
进行中（未招募）
不适用
A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin (Pre- and Post Chemotherapy and Pre-Chemotherapy only) for Reduction in Severity of Oral Mucositis in Subjects with Multiple Myeloma (MM) Receiving High Dose Melphalan followed by Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)Oral Mucositis Induced by High Dose ChemotherapyCataract development associated with palifermin administrationMedDRA version: 8.1Level: LLTClassification code 10028130Term: Mucositis oralMedDRA version: 9.1Level: LLTClassification code 10007739Term: CataractEUCTR2006-003709-15-BEBiovitrum AB (publ)275
进行中（未招募）
不适用
A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin (Pre- and Post Chemotherapy and Pre-Chemotherapy only) for Reduction in Severity of Oral Mucositis in Subjects with Multiple Myeloma (MM) Receiving High Dose Melphalan followed by Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)Oral Mucositis Induced by High Dose ChemotherapyCataract development associated with palifermin administrationMedDRA version: 8.1Level: LLTClassification code 10028130Term: Mucositis oralMedDRA version: 9.1Level: LLTClassification code 10007739Term: CataractEUCTR2006-003709-15-DEBiovitrum AB (publ)275
进行中（未招募）
不适用
A study comparing two different dosing regimens of palifermin (beforeand after chemotherapy versus before chemotherapy) with placebo onthe effect of reducing oral mucositis in patients with multiple myelomawho have been given treatment with high dose melphalan followed bystem cell transplantation.Oral Mucositis Induced by High Dose ChemotherapyCataract development associated with palifermin administrationMedDRA version: 14.0Level: LLTClassification code 10028130Term: Mucositis oralSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.0Level: PTClassification code 10007739Term: CataractSystem Organ Class: 10015919 - Eye disordersEUCTR2006-003709-15-ATSwedish Orphan Biovitrum AB (publ)275
进行中（未招募）
不适用
A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin Pre- and Post Chemotherapy and Pre-Chemotherapy only for Reduction in Severity of Oral Mucositis in Subjects with Multiple Myeloma MM Receiving High Dose Melphalan followed by Autologous Peripheral Blood Stem Cell Transplantation PBSCT - EU PMC in Heme TxMieloma Multiple SubjectMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2006-003709-15-ITAMGEN S.P.A.275